|Bid||248.50 x 0|
|Ask||248.60 x 0|
|Day's range||248.10 - 252.20|
|52-week range||248.10 - 335.85|
|Beta (5Y monthly)||0.15|
|PE ratio (TTM)||18.13|
|Earnings date||27 July 2023|
|Forward dividend & yield||9.50 (3.78%)|
|Ex-dividend date||16 Mar 2023|
|1y target est||364.36|
Roche Holding (VTX:ROG) has had a rough three months with its share price down 8.6%. However, stock prices are usually...
Alnylam's (ALNY) mid-stage study of zilebesiran in the treatment of hypertension in patients at high cardiovascular risk meets primary and key secondary endpoints.
Zilebesiran met primary endpoint demonstrating greater than 15 mmHg reduction of systolic blood pressure at three months of treatment compared to placebo Study met key secondary endpoints showing consistent and sustained reductions of systolic blood pressure at six monthsZilebesiran demonstrated an encouraging safety and tolerability profile in adult patients with mild-to-moderate hypertensionFull study results to be presented at an upcoming scientific conference Basel, 7 September 2023 - Roche